NEW YORK (GenomeWeb News) – The US Food and Drug Administration has approved Quidel's molecular diagnostic assay for detecting Clostridium difficile infections for sale in the US, the San Diego-based company said today.
Quidel this week provided an update on its burgeoning molecular diagnostics pipeline, noting that it hopes to be able to gain US regulatory approval in the next few months for its CE-marked non-instrumented, isothermal amplification-based AmpliVue assay for Clostridium diffic
NEW YORK (GenomeWeb News) – Quidel said after the close of the market Tuesday that revenues in the third quarter narrowed by a fraction of 1 percent year over year, missing the consensus Wall Street estimate.
NEW YORK (GenomeWeb News) – Piper Jaffray on Thursday initiated coverage of diagnostics firm Quidel with an Overweight rating, noting the San Diego-based company's move into the molecular diagnostics space.
The investment bank has a $26 price target on Quidel's stock.
NEW YORK (GenomeWeb News) – In a nod to the growing influence of diagnostic products and services on clinical decisions, investment bank Cowen & Co. today initiated coverage of several firms operating in the molecular diagnostics and 'omics-related life science spaces.
BioHelix is developing a low-cost, handheld, real-time fluorescence detection system capable of running assays based on the company's isothermal helicase-dependent amplification technology, the company disclosed this week.
NEW YORK (GenomeWeb News) – Quidel announced late on Friday it has entered into an amended and restated $140 million, five-year senior secured facility.
Bank of America is the sole lead arranger for the facility, while US Bank National Association is the syndication agent.